Genetic deletion or antibody blockade of SIRPα, CD22, CD33 and PD1 enhance the microglial phagocytic activities against Aβ and glioblastoma, making the receptors attractive therapeutic targets for treating AD and brain tumor (17, 34–36). Here, CD33 is linked to glioblastoma.